135 related articles for article (PubMed ID: 33826946)
1. The pharmacology of the prostaglandin D
Brightling C; Kulkarni S; Lambrecht BN; Sandham D; Weiss M; Altman P
Pulm Pharmacol Ther; 2021 Jun; 68():102030. PubMed ID: 33826946
[TBL] [Abstract][Full Text] [Related]
2. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin D
Carstensen S; Gress C; Erpenbeck VJ; Kazani SD; Hohlfeld JM; Sandham DA; Müller M
Respir Res; 2021 Oct; 22(1):262. PubMed ID: 34620168
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang D; Guo X; Liu T; Li Y; Du Z; Liu C
Curr Allergy Asthma Rep; 2021 Aug; 21(7):39. PubMed ID: 34387775
[TBL] [Abstract][Full Text] [Related]
5. DP
Saunders R; Kaul H; Berair R; Gonem S; Singapuri A; Sutcliffe AJ; Chachi L; Biddle MS; Kaur D; Bourne M; Pavord ID; Wardlaw AJ; Siddiqui SH; Kay RA; Brook BS; Smallwood RH; Brightling CE
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760581
[TBL] [Abstract][Full Text] [Related]
6. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.
Maspero J; Agache IO; Kamei T; Yoshida M; Boone B; Felser JM; Kawakami F; Knorr B; Lawrence D; Lehmann T; Wang W; Pedinoff AJ
Respir Res; 2021 Dec; 22(1):311. PubMed ID: 34895218
[TBL] [Abstract][Full Text] [Related]
8. Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator.
Weiss HM; Langenickel T; Cain M; Kulkarni S; Shah B; Vemula J; Rahmanzadeh G; Poller B
Drug Metab Dispos; 2021 May; 49(5):389-394. PubMed ID: 33632715
[TBL] [Abstract][Full Text] [Related]
9. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
Poller B; Woessner R; Barve A; Tillmann HC; Vemula J; Nica A; Elbast W; Schiller H; End P; Camenisch G; Weiss M
Pulm Pharmacol Ther; 2019 Aug; 57():101809. PubMed ID: 31195091
[TBL] [Abstract][Full Text] [Related]
10. Fevipiprant, an oral prostaglandin DP
Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
[TBL] [Abstract][Full Text] [Related]
11. New treatments for asthma: From the pathogenic role of prostaglandin D
Pelaia C; Crimi C; Vatrella A; Busceti MT; Gaudio A; Garofalo E; Bruni A; Terracciano R; Pelaia G
Pharmacol Res; 2020 May; 155():104490. PubMed ID: 31682916
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?
Murillo JC; Dimov V; Gonzalez-Estrada A
Expert Opin Pharmacother; 2018 Dec; 19(18):2087-2093. PubMed ID: 30394155
[TBL] [Abstract][Full Text] [Related]
13. The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D
Chen W; Luo J; Ye Y; Hoyle R; Liu W; Borst R; Kazani S; Shikatani EA; Erpenbeck VJ; Pavord ID; Klenerman P; Sandham DA; Xue L
J Immunol; 2021 Jun; 206(11):2714-2724. PubMed ID: 34011519
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
Brightling CE; Gaga M; Inoue H; Li J; Maspero J; Wenzel S; Maitra S; Lawrence D; Brockhaus F; Lehmann T; Brindicci C; Knorr B; Bleecker ER
Lancet Respir Med; 2021 Jan; 9(1):43-56. PubMed ID: 32979986
[TBL] [Abstract][Full Text] [Related]
15. The impact of the prostaglandin D
Brightling CE; Brusselle G; Altman P
Allergy; 2020 Apr; 75(4):761-768. PubMed ID: 31355946
[TBL] [Abstract][Full Text] [Related]
16. Investigational prostaglandin D2 receptor antagonists for airway inflammation.
Santini G; Mores N; Malerba M; Mondino C; Macis G; Montuschi P
Expert Opin Investig Drugs; 2016 Jun; 25(6):639-52. PubMed ID: 27094922
[TBL] [Abstract][Full Text] [Related]
17. Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).
Gevaert P; Bachert C; Maspero JF; Cuevas M; Steele D; Acharya S; Altman P
J Allergy Clin Immunol; 2022 May; 149(5):1675-1682.e3. PubMed ID: 35094848
[TBL] [Abstract][Full Text] [Related]
18. Fevipiprant in the treatment of asthma.
White C; Wright A; Brightling C
Expert Opin Investig Drugs; 2018 Feb; 27(2):199-207. PubMed ID: 29363343
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin D
Marone G; Galdiero MR; Pecoraro A; Pucino V; Criscuolo G; Triassi M; Varricchi G
Expert Opin Investig Drugs; 2019 Jan; 28(1):73-84. PubMed ID: 30513028
[TBL] [Abstract][Full Text] [Related]
20. Fevipiprant, a selective prostaglandin D
Hardman C; Chen W; Luo J; Batty P; Chen YL; Nahler J; Wu Y; Pavord ID; Erpenbeck VJ; Sandham DA; Xue L; Ogg G
J Allergy Clin Immunol; 2019 Jun; 143(6):2329-2333. PubMed ID: 30825466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
